QSAR models for predicting the antibacterial activity of some 1-benzylbenzimidazole derivatives

Chemicke Listy

Volumn 102, Issue 15 SPEC. ISS., 2008, Pages

  Podunavac Kuzmanović, Sanja O ^a   Cvetković, Dragoljub D ^a   Barna, Dijana J ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54349110931     PISSN: 00092770     EISSN: 12137103     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Bevan D.: QSAR and Drug Design. Network Science, http://www.netsci.org/Science/Compchem/feature12.html.
2. QSAR, The Australian Computational Chemistry via the InternetProject,www.chem.swin.edu.au/modukes/mod4/index.html.
3. Hansch C.: J. Med. Chem. 19, 1 (1976).
4. Podunavac-Kuzmanović S. O., Markov S. L., Barna D. J.: J. Theor. Comp. Chem. 6, 687 (2007).
5. Podunavac-Kuzmanović, S. O., Barna, D. J., Cvetković D. M .: Acta Periodica Technol. 38, 139 (2007).
6. Perišić-Janjić N. U., Podunavac-Kuzmanović S. O.: J. Planar Chromatogr. 21, 135 (2008).
7. Perišić-Janjić N. U., Podunavac-Kuzmanović S. O., Balaž, J. S., Vlaović Dj.: J. Planar Chromatogr. 13, 123 (2000).
8. Kazimierczuk Z., Upcroft J. A., Upcroft P., Gorska A., Starosciak B., Laudy A.: Acta Biochim. Polon. 49, 185 (2002).
9. . Goker H., Kus C., Boykin D. W., Yildiz S., Altanlar N.: Bioorg. Med. Chem. 17, 2233 (2007).
10. Ozden S., Atabey D., Yildiz D., Goker H.: Bioorg. Med. Chem. 13, 1587 (2005).
11. Podunavac-Kuzmanović S. O ., Cvetković D. M .: Centr. Eur. J. Occupat. Environ. Med.. 12, 55 (2006).
12. Podunavac-Kuzmanović S. O ., Markov S. L.: Centr. Eur. J. Occupat. Environ. Med. 12, 61 (2006).
13. Podunavac-Kuzmanović S. O ., Leovac V. M ., Perišić- Janjić N. U., Rogan J., Balaž J.: J. Serb. Chem. Soc. 64, 381 (1999).
14. Podunavac-Kuzmanović S. O ., Cvetković D.: J. Serb. Chem. Soc. 75, 381 (2007).
15. Kucukbay H., Durmaz R., Orhan E., Gunal S.: Il Farmaco 58, 431 (2003).
16. Kus C., Ayhan-Kilcigil G., Can-Eke B., Iscan M.: Arch. Pharm. Res. 27, 156 (2004).
17. Ayhan-Kilcigil G., Kus C., Coban T., Can-Eke B., Iscan M.: J. Enz. Inhib. Med. Chem. 19, 129 (2004).
18. Ayhan-Kilcigil G., Altanlar N.: Turk. J. Chem. 30, 223 (2006).
19. Mohamed B. G., Hussein M. A ., Abdel-Alim A. M ., Hashem M.: Arch. Pharm. Res. 29, 26 (2006).
20. El-Hawash S. A ., Badawey E. A ., Kappe T.: Pharmazie 54, 341 (1999).
21. Soderlind K. J., Gorodetsky B., Singh A., Bachur N., Miller G., Lown J.: Anti Canc. Drug Des. 14, 19 (1999).
22. Nakano H., Inoue T., Kawasaki N., Miyataka H., Matsumoto H., Taguchi T., Inagaki N., Nagai H., Satoh T.: Chem. Pharm. Bull. 47, 1573 (1999).
23. Demirayak S., Abu-Mohsen U., Cagri Karaburun A.: Eur. J. Med. Chem. 37, 255 (2002).
24. R ida S. M., El-Hawash S. A., Fahmy H. T., Hazzaa A. A., El-Meligy M. M.: Arch. Pharm. Res. 29, 826 (2006).
25. Vlaović Crossed D sign., Čanadanović-Brunet J., Balaž J., Juranić I., Crossed D signoković D., Mackenzie K.: Biosci. Biotech. Biochem. 56, 199 (1992).
26. National Committee for Clinical Laboratory Standards, NCCLS Approval Standard Document M2-A7. Vilanova, Pa, U.S.A. 2000.
27. National Committee for Clinical Laboratory Standards, NCCLS Approval Standard Document M7-A5. Vilanova, Pa, U.S.A. 2000.
28. HyperChem 7.5, Hypercube, Inc., 419 Phillip St., Waterloo, Ontario, Canada N2L 3X2.
29. Dragon 5 Evaluation version, 2004, Talete SRL, Milano, Italy.
30. CS. Chem. Office, Version 7.0, Cambridge Soft Corporation, 100 Cambridge Park Drive, Cambridge, MA 02140-2317, U.S.A. 2001.
31. www.ncss.com.
32. Jalali-Heravi M., Kyani A.: J. Chem. Inf. Comput. Sci. 44, 1328 (2004).